Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is strongly associated with obesity-related ectopic fat accumulation in the liver. Hepatic lipid accumulation encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. Given that dysregulated hepatic lipid metabolism may be an onset factor in NAFLD, understanding how hepatic lipid metabolism is modulated in healthy subjects and which steps are dysregulated in NAFLD subjects is crucial to identify effective therapeutic targets. Additionally, hepatic inflammation is involved in chronic hepatocyte damage during NAFLD progression. As a key immune signaling hub that mediates NF-κB activation, the IκB kinase (IKK) complex, including IKKα, IKKβ, and IKKγ (NEMO), has been studied as a crucial regulator of the hepatic inflammatory response and hepatocyte survival. Notably, TANK-binding kinase 1 (TBK1), an IKK-related kinase, has recently been revealed as a potential link between hepatic inflammation and energy metabolism. Here, we review (1) the biochemical steps of hepatic lipid metabolism; (2) dysregulated lipid metabolism in obesity and NAFLD; and (3) the roles of IKKs and TBK1 in obesity and NAFLD.
Highlights
nonalcoholic steatohepatitis (NASH) is characterized by steatosis with hepatocyte injury in the form of ballooning hepatocytes, which is associated with hepatocyte death, apoptosis, and inflammation[5]
We summarize the molecular mechanism of hepatic fatty acid (FA) metabolism regulation under normal and nonalcoholic fatty liver disease (NAFLD) pathophysiological conditions
Obesity-related inflammation and insulin resistance are associated with hepatic lipid accumulation and systemic inflammation, which contribute to NAFLD development
Summary
The prevalence of obesity (excess fat storage) due to high-calorie food intake and a sedentary lifestyle is greatly increasing. SREBP-1c, a key transcriptional modulator of lipogenic enzymes, is activated by insulin in response to feeding, thereby increasing the expression of DNL-related genes[57]. Inefficient hepatic lipid disposal eventually leads to the accumulation of acetyl-CoA, promoting DNL and conversion to FA metabolites, including DG, which may suppress insulin receptor signaling through PKCε activation (Fig. 2)[11,89].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.